# EDGAR Filing Document

**Accession Number:** 0001740279
**File Stem:** 0000000000-26-000935
**Filing Date:** 2026-1
**Character Count:** 2343
**Document Hash:** eb732e6c0ff6f2c2118660aa1f8ca951
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-000935.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0000000000-26-000935

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260127

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IN8BIO, INC.
- **CENTRAL INDEX KEY:** 0001740279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825462585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-292830

**BUSINESS ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118
- **BUSINESS PHONE:** (646) 600-6438

**MAIL ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incysus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20180510
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-016752

## Text-Extract

```

                                                           January 23, 2026

William Ho
President and Chief Executive Officer
IN8bio, Inc.
350 5th Avenue, Suite 5330
New York, NY 10118

       Re: IN8bio, Inc.
           Registration Statement on Form S-3
           Filed January 20, 2026
           File No. 333-292830
Dear William Ho:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jessica Dickerson at 202-551-8013 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Jaime L. Chase, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._